Cutler Group’s Briacell Therapeutics BCTX Stock Holding History

Cutler Group’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9	Closed	-$7K	–	4387
2022 Q3	$7K	Buy	9 +7	+350%	+$7.02K	﹤0.01%	3358
2022 Q2	$2K	Buy	+2	New	+$1.98K	﹤0.01%	4228

Other funds holding BCTX

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Simplex Trading

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Cutler Group's BCTX Position: Q4 2022 in Review

Cutler Group sold out of Briacell Therapeutics (BCTX) in Q4 2022, closing a stake of 9 shares — an estimated $7K sold.

Cutler Group first reported a position in BCTX in Q2 2022 and held it in 2 quarters. The position peaked at $7K in Q3 2022. 18 funds tracked by Wall St. Rank hold BCTX as of Q4 2022.

Cutler Group reported no remaining Briacell Therapeutics position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 9 Briacell Therapeutics shares in Q4 2022, an estimated $7K.
Cutler Group first reported a position in Briacell Therapeutics in Q2 2022 and held it in 2 quarters.
Cutler Group's Briacell Therapeutics position peaked at $7K in Q3 2022.
18 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.